Thus, the introduction and application of reliable molecular techniques to the early detection and quantitation of TP53-, ATM- and BIRC3-deletions would improve the predictive and prognostic opportunities in CLL patients. Here, BIRC3 is linked to B-cell chronic lymphocytic leukemia.